Keywords: Radiomics, Breast, HER2 expressing; MRI; Deep learning; PrognosisTo the best of our knowledge, our study is the first to non-invasively assess human epidermal growth factor receptor 2 (HER2) status, especially HER2-low-positive status in breast cancer. In this study, a deep learning radiomics (DLR) model based on contrast-enhanced MRI was constructed and showed high and stable performance in predicting HER2 status in both the training and validation cohorts, and the predicted status was an independently significant predictor of disease-free survival (DFS) in HER2-low-positive/HER2-zero breast cancers. The DLR model showed prospects as a computer-aided diagnostic tool to help more accurately identify HER2-low-positive breast cancers, thereby guiding patient treatment strategies.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords